Fatigue one of the most common and consequential symptoms of MS, yet it remains one of the most challenging symptoms to treat.
This presentation aims to summarize the most frequently studied and promising rehabilitative and pharmacological treatments for MS-related fatigue. Pertinent study findings, knowledge gaps, and opportunities for future research directions will be discussed. The epidemiology and impact of MS-related fatigue will also be briefly reviewed.
Invited presentation for ACTRIMS-ECTRIMS MSVirtual2020 Session PS13: Innovations in Symptomatic and Rehabilitative Therapy.
Review of the most commonly used and promising non-pharmacological (cognitive behavioral therapy, exercise-based strategies) and pharmacological (amantadine, modafinil, and methylphenidate) treatments for MS fatigue, including supporting literature.
Multiple rehabilitative (non-pharmacological) and pharmacological treatments have been studied for MS-fatigue. Non-pharmacological treatments including cognitive behavioral therapy and exercise-based strategies have shown promise, with some demonstrating moderate efficacy in clinical trials. Additional research that incorporates individual patient traits, multimodal fatigue measures, and important effect modifiers is necessary to better understand the most appropriate role for pharmacological treatments, treatment sequencing, and combination therapies to optimize fatigue management for persons with MS.